Background: Changes in communicative functions are common in Parkinson’s disease (PD), but there are only limited data provided by individuals with PD on how these changes are perceived, what their consequences are, and what type of intervention is provided. Aim: To present self-reported information about speech and communication, the impact on communicative participation, and the amount and type of speech-language pathology services received by people with PD. Methods: Respondents with PD recruited via the Swedish Parkinson’s Disease Society filled out a questionnaire accessed via a Web link or provided in a paper version. Results: Of 188 respondents, 92.5% reported at least one symptom related to communication; the most common symptoms were weak voice, word-finding difficulties, imprecise articulation, and getting off topic in conversation. The speech and communication problems resulted in restricted communicative participation for between a quarter and a third of the respondents, and their speech caused embarrassment sometimes or more often to more than half. Forty-five percent of the respondents had received speech-language pathology services. Conclusions: Most respondents reported both speech and language symptoms, and many experienced restricted communicative participation. Access to speech-language pathology services is still inadequate. Services should also address cognitive/linguistic aspects to meet the needs of people with PD.

Keywords:
Speech, Voice, Swallowing, Communication skills, Dysarthria, Parkinson’s disease, Speech-language pathology, Quality of life, Service provision
1.
von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R: Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473–490.
2.
Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S: Speech impairment in a large sample of people with Parkinson’s disease. Behav Neurol 1998; 11: 131–137.
3.
Miller N, Allcock L, Jones D, Noble E, Hildreth AJ, Burn D: Prevalence and pattern of perceived intelligibility changes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 1188–1190.
4.
Hartelius L, Svensson P: Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop 1994; 46: 9–17.
5.
Miller N, Noble E, Jones D, Allcock L, Burn DJ: How do I sound to me? Perceived changes in communication in Parkinson’s disease. Clin Rehabil 2008; 22: 14–22.
6.
Miller N, Noble E, Jones D, Burn D: Life with communication changes in Parkinson’s disease. Age Ageing 2006; 35: 235–239.
7.
Grossman M, Lee C, Prather P, Kalmanson J, Stern MB, Hurtig HI: Information processing speed and sentence comprehension in Parkinson’s disease. Neuropsychology 2002; 16: 174–181.
8.
Dauwerse L, Hendrikx A, Schipper K, Struiks-ma C, Abma TA: Quality-of-life of patients with Parkinson’s disease. Brain Inj 2014; 28: 1342–1352.
9.
Barnish E, Whibley D, Horton SC, Butterfint Z, Deane KHO: Roles of cognitive status and intelligibility in everyday communication in people with Parkinson’s disease: a systematic review. J Parkinsons Dis 2016; 6: 453–462.
10.
Schrag A, Jahanshahi M, Quinn N: How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112–1118.
11.
McAuliffe MJ, Baylor CJ, Yorkston KM: Variables associated with communicative participation in Parkinson’s disease and its relationship to measures of health-related quality- of-life. Int J Speech Lang Pathol 2017; 19: 407–417.
12.
Baylor C, Yorkston K, Eadie T, Kim J, Chung H, Amtmann D: The Communicative Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic short form. J Speech Lang Hear Res 2013; 56: 1190–1208.
13.
Suttrup I, Warnecke T: Dysphagia in Parkinson’s disease. Dysphagia 2016; 31: 24–32.
14.
Kalf JG, de Swart BJM, Bloem BR, Munneke M: Prevalence of oropharyngeal dysphagia in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord 2012; 18: 311–315.
15.
Clarke CE, Zobkiw RM, Gullaksen E: Quality of life and care in Parkinson’s disease. Br J Clin Pract 1995; 49: 288–293.
16.
Eadie TL, Yorkston KM, Klasner ER, Dudgeon BJ, Deitz JC, Baylor CR, Miller RM, Amt mann D: Measuring communicative participation: a review of self-report instruments in speech-language pathology. Am J Speech Lang Pathol 2006; 15: 307–320.
17.
Gray C, Baylor C, Eadie T, Kendall D, Yorkston K: The Levels of Speech Usage rating scale: comparison of client self-ratings with speech pathologist ratings. Int J Lang Commun Disord 2012; 47: 333–344.
18.
Johansson K, Hartelius L, Schalling E: Self-reported speech, communication and swallowing changes in multiple sclerosis. 2016, unpublished manuscript.
19.
Aarsland D: Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord 2016; 22(suppl 1): S144–S148.
20.
Saldert C, Ferm U, Bloch S: Semantic trouble sources and their repair in conversations affected by Parkinson’s disease. Int J Lang Commun Disord 2014; 49: 710–721.
21.
Baylor C, Yorkston K, Bamer A, Britton D, Amtmann D: Variables associated with communicative participation in people with multiple sclerosis: a regression analysis. Am J Speech Lang Pathol 2010; 19: 143–153.
22.
Cantor F: Central and peripheral fatigue: exemplified by multiple sclerosis and myasthenia gravis. PM R 2010; 2: 399–405.
23.
Krupp LB, Pollina DA: Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996; 9: 456–460.
24.
Makashay MJ, Cannard KR, Solomon NP: Speech-related fatigue and fatigability in Parkinson’s disease. Clin Linguist Phon 2015; 29: 27–45.
25.
Abe K, Takanashi M, Yanagihara T: Fatigue in patients with Parkinson’s disease. Behav Neurol 2000; 12: 103–106.
26.
Herlofson K, Larsen JP: The influence of fatigue on health-related quality of life in patients with Parkinson’s disease. Acta Neurol Scand 2003; 107: 1–6.
27.
Baylor C, Burns M, Eadie T, Britton D, Yorkston K: A qualitative study of inter-ference with communicative participation across communication disorders in adults. Am J Speech Lang Pathol 2011; 20: 269–287.
28.
Miller N, Deane KHO, Jones D, Noble E, Gibb C: National survey of speech and language therapy provision for people with Parkinson’s disease in the United Kingdom: therapists’ practices. Int J Lang Commun Disord 2011; 46: 189–201.
29.
Carlsson E, Hartelius L, Saldert C: Communicative strategies used by spouses of individuals with communication disorders related to stroke-induced aphasia and Parkinson’s disease. Int J Lang Commun Disord 2014; 49: 722–735.
30.
Simmons-Mackie N, Raymer A, Cherney LR: Communication partner training in aphasia: an updated systematic review. Arch Phys Med Rehabil 2016; 97: 2202–2221.e8.
31.
Lock S, Wilkinson R, Bryan K: Supporting Partners of People with Aphasia in Relationships and Conversation (SPPARC). Milton Keynes, Speechmark Publishing Ltd, 2001.
32.
Forsgren E, Antonsson M, Saldert C: Training conversation partners of persons with communication disorders related to Parkinson’s disease – a protocol and a pilot study. Logo-ped Phoniatr Vocol 2013; 38: 82–90.
33.
Weiner WJ, Singer C: Parkinson’s disease and nonpharmacologic treatment programs. J Am Geriatr Soc 1989; 37: 359–363.
34.
Ramig LO, Sapir S, Countryman S, Pawlas AA, O’Brien C, Hoehn M, Thompson LL: Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001; 71: 493–498.
35.
Sapir S, Spielman JL, Ramig LO, Story BH, Fox C: Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res 2007; 50: 899–912.
36.
Dumer AI, Oster H, McCabe D, Rabin LA, Spielman JL, Ramig LO, Borod JC: Effects of the Lee Silverman Voice Treatment (LSVT® LOUD) on hypomimia in Parkinson’s disease. J Int Neuropsychol Soc 2014; 20: 302–312.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.